The world needs to have a stable, manifold and multi-sourced answer at the ready, for the next Ebola outbreak. I do wonder though, how it might feel — to later learn that, as a study subject — the dose you (blindly) received was ineffective. Obviously, each participant should then receive a free dose of the Merck- (or other) known to be effective vaccine. But the only way we will ever know, will probably be when another outbreak arrives — and thousands are dying in the streets of Sierra Leone, Liberia or Guinea. [That’s Stage 2 of the study, as designed — let’s hope the dying doesn’t get here, first.] That’s a sobering thought, for medical ethicists, on a Friday. Here’s a bit:
. . . .The French National Institute of Health and Medical Research (Inserm), the US National Institutes of Health (NIH) and the London School of Hygiene & Tropical Medicine (LSHTM), in collaboration with health authorities in Guinea and Liberia, are launching a large clinical trial of candidate Ebola vaccines under the aegis of the PREVAC international consortium (Partnership for Research on Ebola Vaccination).
This trial seeks to identify vaccination regimens that hold the most promise to protect people from Ebola virus disease in order to prevent or quickly control a future outbreak. More than 5,000 adults and children living in countries at the epicenter of the 2014-16 West Africa Ebola epidemic will be enrolled. An additional site in Sierra Leone is also being planned. The PREVAC trial results from a research partnership that involves Inserm, NIH, LSHTM, and the West African Clinical Research Consortium.
The pharmaceutical companies Janssen Vaccines & Prevention B.V., part of the Janssen Pharmaceutical Companies of Johnson & Johnson, Bavarian Nordic and Merck Sharp Dohme, Corp (MSD outside USA and Canada), are supplying the experimental vaccines being tested in the PREVAC trial. . . .
Onward — outside: crystal clear and icy cold. Inside: on fire, to get on with my. . . life.